These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 20484616)

  • 1. Pharmacokinetics of dexrazoxane in subjects with impaired kidney function.
    Brier ME; Gaylor SK; McGovren JP; Glue P; Fang A; Aronoff GR
    J Clin Pharmacol; 2011 May; 51(5):731-8. PubMed ID: 20484616
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose-independent pharmacokinetics of the cardioprotective agent dexrazoxane in dogs.
    Baldwin JR; Lewis RC; Phillips BA; Overmyer SK; Hatfield NZ; Narang PK
    Biopharm Drug Dispos; 1996 Aug; 17(6):541-50. PubMed ID: 8866044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis.
    Chen N; Lau H; Kong L; Kumar G; Zeldis JB; Knight R; Laskin OL
    J Clin Pharmacol; 2007 Dec; 47(12):1466-75. PubMed ID: 17954615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of anakinra in subjects with different levels of renal function.
    Yang BB; Baughman S; Sullivan JT
    Clin Pharmacol Ther; 2003 Jul; 74(1):85-94. PubMed ID: 12844139
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical pharmacokinetics of gabapentin after administration of gabapentin enacarbil extended-release tablets in patients with varying degrees of renal function using data from an open-label, single-dose pharmacokinetic study.
    Lal R; Sukbuntherng J; Luo W; Chen D; Blumenthal R; Ho J; Cundy KC
    Clin Ther; 2012 Jan; 34(1):201-13. PubMed ID: 22206794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of severe renal impairment on the pharmacokinetics of clazosentan.
    Bruderer S; Sasu B; Tsvitbaum N; Dingemanse J
    J Clin Pharmacol; 2011 Mar; 51(3):413-21. PubMed ID: 20926750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of the effects of renal impairment on the pharmacokinetic profile of laninamivir, a novel neuraminidase inhibitor, after a single inhaled dose of its Prodrug, CS-8958.
    Ishizuka H; Yoshiba S; Yoshihara K; Okabe H
    J Clin Pharmacol; 2011 Feb; 51(2):243-51. PubMed ID: 20197485
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stereoselective metabolism of dexrazoxane (ICRF-187) and levrazoxane (ICRF-186).
    Hasinoff BB; Aoyama RG
    Chirality; 1999; 11(4):286-90. PubMed ID: 10224655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relative plasma levels of the cardioprotective drug dexrazoxane and its two active ring-opened metabolites in the rat.
    Hasinoff BB; Aoyama RG
    Drug Metab Dispos; 1999 Feb; 27(2):265-8. PubMed ID: 9929514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential effect of chronic renal failure on the pharmacokinetics of lidocaine in patients receiving and not receiving hemodialysis.
    De Martin S; Orlando R; Bertoli M; Pegoraro P; Palatini P
    Clin Pharmacol Ther; 2006 Dec; 80(6):597-606. PubMed ID: 17178261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic study of memantine in healthy and renally impaired subjects.
    Periclou A; Ventura D; Rao N; Abramowitz W
    Clin Pharmacol Ther; 2006 Jan; 79(1):134-43. PubMed ID: 16413248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is the volume of distribution of digoxin reduced in patients with renal dysfunction? Determining digoxin pharmacokinetics by fluorescence polarization immunoassay.
    Cheng JW; Charland SL; Shaw LM; Kobrin S; Goldfarb S; Stanek EJ; Spinler SA
    Pharmacotherapy; 1997; 17(3):584-90. PubMed ID: 9165563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I trial of 96-hour continuous infusion of dexrazoxane in patients with advanced malignancies.
    Tetef ML; Synold TW; Chow W; Leong L; Margolin K; Morgan R; Raschko J; Shibata S; Somlo G; Yen Y; Groshen S; Johnson K; Lenz HJ; Gandara D; Doroshow JH
    Clin Cancer Res; 2001 Jun; 7(6):1569-76. PubMed ID: 11410492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tigecycline pharmacokinetics in subjects with various degrees of renal function.
    Korth-Bradley JM; Troy SM; Matschke K; Muralidharan G; Fruncillo RJ; Speth JL; Raible DG
    J Clin Pharmacol; 2012 Sep; 52(9):1379-87. PubMed ID: 21953572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and safety of single-dose ribavirin in patients with chronic renal impairment.
    Gupta SK; Kantesaria B; Glue P
    Drug Discov Ther; 2013 Aug; 7(4):158-63. PubMed ID: 24071578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Feasibility and pharmacokinetic study of infusional dexrazoxane and dose-intensive doxorubicin administered concurrently over 96 h for the treatment of advanced malignancies.
    Chow WA; Synold TW; Tetef ML; Longmate J; Frankel P; Lawrence J; Al-Khadimi Z; Leong L; Lim D; Margolin K; Morgan RJ; Raschko J; Shibata S; Somlo G; Twardowski P; Yen Y; Doroshow JH
    Cancer Chemother Pharmacol; 2004 Sep; 54(3):241-8. PubMed ID: 15173955
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and pharmacodynamics of lobaplatin (D-19466) in patients with advanced solid tumors, including patients with impaired renal of liver function.
    Welink J; Boven E; Vermorken JB; Gall HE; van der Vijgh WJ
    Clin Cancer Res; 1999 Sep; 5(9):2349-58. PubMed ID: 10499604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of renal function on the pharmacokinetics of palifermin.
    Gillespie B; Zia-Amirhosseini P; Salfi M; Kakkar T; Wang J; Gupta S; Smith B; Robson R; Sullivan JT
    J Clin Pharmacol; 2006 Dec; 46(12):1460-8. PubMed ID: 17101745
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Garenoxacin pharmacokinetics in subjects with renal impairment.
    Krishna G; Gajjar D; Swan S; Marbury T; Grasela DM; Wang Z
    Curr Med Res Opin; 2007 Mar; 23(3):649-57. PubMed ID: 17355746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of pilocarpine in subjects with varying degrees of renal function.
    St Peter JV; Lambrecht LJ; Gunderson BW; Andersen SA; Gallagher SC; Swan SK
    J Clin Pharmacol; 2000 Dec; 40(12 Pt 2):1470-5. PubMed ID: 11185668
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.